The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine, reported news agency ANI.
Earlier in mid-December, the company sought permission to conduct clinical trials for its intranasal booster dose.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
Bharat Biotech also manufactures the COVID-19 vaccine Covaxin, which was recently given emergency use authorisation for 12-18 year olds.
'Vande Mataram' Row Sparks Outrage: Muslim Activists Condemn MLA Abu Asim Azmi's Stance And Minister Mangal Prabhat Lodha's Retaliation
Bombay HC Permits 15-Year-Old Rape Survivor With Borderline IQ To Terminate 27-Week Pregnancy; Cites Grave Mental Health Risks
Bombay HC Acquits Man After 27 Years In Wife’s Alleged Suicide Case; Cites ‘Mere Unhappiness Not Proof Of Cruelty'
Bombay HC To Hear Amol Palekar’s Petition Challenging Mandatory Pre-Censorship Of Plays On December 5
(With inputs from Agencies)
